JP2022512326A5 - - Google Patents
Info
- Publication number
- JP2022512326A5 JP2022512326A5 JP2021532126A JP2021532126A JP2022512326A5 JP 2022512326 A5 JP2022512326 A5 JP 2022512326A5 JP 2021532126 A JP2021532126 A JP 2021532126A JP 2021532126 A JP2021532126 A JP 2021532126A JP 2022512326 A5 JP2022512326 A5 JP 2022512326A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776012P | 2018-12-06 | 2018-12-06 | |
| US62/776,012 | 2018-12-06 | ||
| PCT/US2019/064757 WO2020118094A1 (en) | 2018-12-06 | 2019-12-05 | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512326A JP2022512326A (ja) | 2022-02-03 |
| JP2022512326A5 true JP2022512326A5 (https=) | 2022-12-09 |
| JPWO2020118094A5 JPWO2020118094A5 (https=) | 2022-12-09 |
| JP7571021B2 JP7571021B2 (ja) | 2024-10-22 |
Family
ID=70974859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532126A Active JP7571021B2 (ja) | 2018-12-06 | 2019-12-05 | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210369776A1 (https=) |
| JP (1) | JP7571021B2 (https=) |
| KR (1) | KR20210112310A (https=) |
| CN (1) | CN113226335B (https=) |
| SG (1) | SG11202105975SA (https=) |
| TW (1) | TW202039545A (https=) |
| WO (1) | WO2020118094A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020014285A2 (en) | 2018-07-09 | 2020-01-16 | Intrexon Corporation | Fusion constructs and methods of using thereof |
| CN111718409B (zh) * | 2020-06-17 | 2021-03-02 | 深圳豪石生物科技有限公司 | 一种t细胞受体及其应用 |
| EP4178680A4 (en) * | 2020-07-10 | 2024-07-31 | Precigen, Inc. | FUSION CONSTRUCTS AND THEIR METHODS OF USE |
| CN112940108B (zh) * | 2021-03-19 | 2022-10-14 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| CN116179493A (zh) * | 2021-09-29 | 2023-05-30 | 成都美杰赛尔生物科技有限公司 | 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用 |
| US20260078163A1 (en) * | 2022-09-06 | 2026-03-19 | Board Of Regents, The University Of Texas System | T-cell receptor that targets egfr mutation and methods of using the same |
| WO2024173916A1 (en) * | 2023-02-17 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of preventing t cell exhaustion |
| CN119390814B (zh) * | 2023-10-26 | 2025-06-27 | 上海市第一人民医院 | 一种t细胞受体及其制备方法和用途 |
| CN119978143B (zh) * | 2025-01-26 | 2025-10-21 | 湖南大学 | 一种基于synNotch的工程化巨噬细胞及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002941A1 (en) * | 2004-01-23 | 2006-01-05 | Vievax Corp. | Compositions comprising immune response altering agents and methods of use |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) * | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2017040945A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| KR20190003938A (ko) * | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| US11549099B2 (en) * | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| US12060394B2 (en) * | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| WO2018162563A1 (en) * | 2017-03-07 | 2018-09-13 | Universität Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| AU2018254517A1 (en) * | 2017-04-19 | 2019-12-05 | University Of Southern California | Compositions and methods for treating cancer |
| JP7340458B2 (ja) * | 2017-05-09 | 2023-09-07 | アメリカ合衆国 | Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ |
-
2019
- 2019-12-05 WO PCT/US2019/064757 patent/WO2020118094A1/en not_active Ceased
- 2019-12-05 JP JP2021532126A patent/JP7571021B2/ja active Active
- 2019-12-05 CN CN201980081064.XA patent/CN113226335B/zh active Active
- 2019-12-05 SG SG11202105975SA patent/SG11202105975SA/en unknown
- 2019-12-05 KR KR1020217019705A patent/KR20210112310A/ko active Pending
- 2019-12-05 US US17/311,114 patent/US20210369776A1/en not_active Abandoned
- 2019-12-06 TW TW108144761A patent/TW202039545A/zh unknown
-
2024
- 2024-12-04 US US18/968,399 patent/US20250243293A1/en active Pending